Very little new info here. Quite disappointing. DM even acknowledged that the slide describing the proposed trial was outdated. Why use an outdated slide? The slide indicated 1800 patients minimum and DM said they are going to make it a bigger trial than that. For locations the slide listed Europe and US sites, but he said Europe and probably Asia and that they might do US but aren't sure if that is available yet. Like bfw indicated, still targeting an H2 start for BETonMACE. In the last slide, there were two items of interest in terms of trial timelines:

1) BETonMACE phase 3 enrollment launch 2H 2015

2) Phase 2/3 orphan indication announcement and launch 2015

Hopefully more clarity from Resverlogix at the June 30th special meeting.....